{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:57:00Z","timestamp":1791827820668,"version":"4.3.4"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Gut microbiota dysbiosis plays an important role in the progression of non-alcoholic fatty liver disease (NAFLD), and no approved drugs are available for NAFLD treatment. In this study, we aimed to explore the dynamic changes of gut microbiota at the different stages of NAFLD and determine whether ursodeoxycholic acid (UDCA) could improve liver histopathological features of non-alcoholic steatohepatitis (NASH) mice induced by a high-fat high-cholesterol (HFHC) diet and its impact on gut microbiota. 6-week-old male C57BL\/6 mice were fed with a HFHC or normal diet for 12, 18, and 24\u00a0weeks, respectively, to simulate the different stages of NAFLD. 16s ribosomal RNA genes from mice fecal samples at the different time points were sequenced to evaluate the dynamic changes of the gut microbiota. Then, C57BL\/6 mice were fed with a HFHC diet for 24\u00a0weeks to establish the NASH model. Different doses of UDCA were administered intragastrically for additional 4\u00a0weeks. Normal diet\u2013fed mice were taken as control. Serum samples, liver, and intestine tissues were harvested for biochemical tests and histopathological examinations. 16s ribosomal RNA genes from mice fecal samples were sequenced to assess the structural changes of gut microbiota. HFHC diet\u2013fed mice developed simple steatosis, steatohepatitis, and fibrosis at 12, 18, and 24 weeks, respectively. The profile of gut microbiota dynamically changed with the different stages of NAFLD. NASH mice had significantly higher abundance of Fecalibaculum, <jats:italic>Coriobacteriaceae<\/jats:italic>_UCG-002, and <jats:italic>Enterorhabdus<\/jats:italic>, and lower abundance of norank_f_<jats:italic>Muribaculaceae<\/jats:italic>, Bacteroides, and Alistipes, which were partially restored by UDCA treatment. UDCA treatment significantly attenuated hepatic inflammation of NASH mice as indicated by the sum of ballooning and lobular inflammation of the NALFD activity score (3.2 \u00b1 0.8 vs 1.8 \u00b1 0.8, <jats:italic>p<\/jats:italic> = 0.029), and partially restored gut microbiota dysbiosis, and increased the expression of Claudin-1 and ZO-1 in the intestine, but did not activate the suppressed Farnesoid X receptor signal pathway. Conclusions: The gut microbiota dynamically changes with the different stages of NAFLD. UDCA treatment (120\u00a0mg\/kg) could partially restore gut microbiota, repair gut barrier integrity, and attenuate hepatic inflammation in the NASH mouse model.<\/jats:p>","DOI":"10.3389\/fphar.2021.788558","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T10:00:38Z","timestamp":1638784838000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":71,"title":["Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model"],"prefix":"10.3389","volume":"12","author":[{"given":"Hu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizhan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut Microbiota and Human NAFLD: Disentangling Microbial Signatures from Metabolic Disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.3748\/wjg.v25.i33.4904","article-title":"Towards a Standard Diet-Induced and Biopsy-Confirmed Mouse Model of Non-alcoholic Steatohepatitis: Impact of Dietary Fat Source","volume":"25","author":"Boland","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1872-034X.2011.00820.x","article-title":"Ursodeoxycholic Acid Dose-Dependently Improves Liver Injury in Rats Fed a Methionine- and Choline-Deficient Diet","volume":"41","author":"Buko","year":"2011","journal-title":"Hepatol. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.bbalip.2019.07.006","article-title":"Ursodeoxycholic Acid Is a GPBAR1 Agonist and Resets Liver\/intestinal FXR Signaling in a Model of Diet-Induced Dysbiosis and NASH","volume":"1864","author":"Carino","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cel Biol Lipids"},{"key":"B5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","article-title":"Fastp: an Ultra-fast All-In-One FASTQ Preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/archsurg.1970.01340280030009","article-title":"Intestinal Mucosal Lesion in Low-Flow States. I. A Morphological, Hemodynamic, and Metabolic Reappraisal","volume":"101","author":"Chiu","year":"1970","journal-title":"Arch. Surg."},{"key":"B8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41587-020-0548-6","article-title":"PICRUSt2 for Prediction of Metagenome Functions","volume":"38","author":"Douglas","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/nmeth.2604","article-title":"UPARSE: Highly Accurate OTU Sequences from Microbial Amplicon Reads","volume":"10","author":"Edgar","year":"2013","journal-title":"Nat. Methods"},{"key":"B10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New Trends on Obesity and NAFLD in Asia","volume":"67","author":"Fan","year":"2017","journal-title":"J. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s11745-017-4242-5","article-title":"Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in \u03b2-Muricholic Acid, a Farnesoid X Receptor Antagonist","volume":"52","author":"Fujita","year":"2017","journal-title":"Lipids"},{"key":"B12","doi-asserted-by":"publisher","first-page":"11874","DOI":"10.1038\/s41598-018-30349-1","article-title":"Ursodeoxycholic Acid Improves Liver Function via Phenylalanine\/tyrosine Pathway and Microbiome Remodelling in Patients with Liver Dysfunction","volume":"8","author":"Kim","year":"2018","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The Role of the Gut Microbiota in NAFLD","volume":"13","author":"Leung","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-dose Ursodeoxycholic Acid Therapy for Nonalcoholic Steatohepatitis: a Double-Blind, Randomized, Placebo-Controlled Trial","volume":"52","author":"Leuschner","year":"2010","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/toxsci\/kfu151","article-title":"Potency of Individual Bile Acids to Regulate Bile Acid Synthesis and Transport Genes in Primary Human Hepatocyte Cultures","volume":"141","author":"Liu","year":"2014","journal-title":"Toxicol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"109873","DOI":"10.1016\/j.biopha.2020.109873","article-title":"Investigation of Gut Microbiome Changes in Type 1 Diabetic Mellitus Rats Based on High-Throughput Sequencing","volume":"124","author":"Ma","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1093\/bioinformatics\/btr507","article-title":"FLASH: Fast Length Adjustment of Short Reads to Improve Genome Assemblies","volume":"27","author":"Magoc","year":"2011","journal-title":"Bioinformatics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/hep.30577","article-title":"The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic Steatosis","volume":"70","author":"Mehal","year":"2019","journal-title":"Hepatology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic Acid Exerts Farnesoid X Receptor-Antagonistic Effects on Bile Acid and Lipid Metabolism in Morbid Obesity","volume":"62","author":"Mueller","year":"2015","journal-title":"J. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of Current Treatments on Liver Disease, Glucose Metabolism and Cardiovascular Risk in Non-alcoholic Fatty Liver Disease (NAFLD): a Systematic Review and Meta-Analysis of Randomised Trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s00535-015-1104-x","article-title":"Beneficial Effects of Combined Ursodeoxycholic Acid and Angiotensin-II Type 1 Receptor Blocker on Hepatic Fibrogenesis in a Rat Model of Nonalcoholic Steatohepatitis","volume":"51","author":"Namisaki","year":"2016","journal-title":"J. Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-cirrhotic, Non-alcoholic Steatohepatitis (FLINT): a Multicentre, Randomised, Placebo-Controlled Trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications for Liver Transplant and Ethnic and Gender Variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile Acids: Natural Ligands for an Orphan Nuclear Receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s13105-014-0336-1","article-title":"Bile Acid Supplementation Improves Established Liver Steatosis in Obese Mice Independently of Glucagon-like Peptide-1 Secretion","volume":"70","author":"Quintero","year":"2014","journal-title":"J. Physiol. Biochem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","article-title":"A Randomized Controlled Trial of High-Dose Ursodesoxycholic Acid for Nonalcoholic Steatohepatitis","volume":"54","author":"Ratziu","year":"2011","journal-title":"J. Hepatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1177\/2050640618804444","article-title":"Fecal SCFAs and SCFA-Producing Bacteria in Gut Microbiome of Human NAFLD as a Putative Link to Systemic T-Cell Activation and Advanced Disease","volume":"6","author":"Rau","year":"2018","journal-title":"United Eur. Gastroenterol J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic Steatohepatitis: A Review","volume":"323","author":"Sheka","year":"2020","journal-title":"Jama"},{"key":"B33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/s1499-3872(17)60019-5","article-title":"Gut Microbiota Dysbiosis in Patients with Non-alcoholic Fatty Liver Disease","volume":"16","author":"Shen","year":"2017","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/his.12662","article-title":"Comparison of Immunoreactive Score, HER2\/neu Score and H Score for the Immunohistochemical Evaluation of Somatostatin Receptors in Bronchopulmonary Neuroendocrine Neoplasms","volume":"67","author":"Specht","year":"2015","journal-title":"Histopathology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited after a Decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.celrep.2018.12.028","article-title":"Parabacteroides Distasonis Alleviates Obesity and Metabolic Dysfunctions via Production of Succinate and Secondary Bile Acids","volume":"26","author":"Wang","year":"2019","journal-title":"Cell Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1128\/aem.00062-07","article-title":"Naive Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy","volume":"73","author":"Wang","year":"2007","journal-title":"Appl. Environ. Microbiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological Features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.788558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T10:00:41Z","timestamp":1638784841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.788558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":38,"alternative-id":["10.3389\/fphar.2021.788558"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.788558","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,6]]},"article-number":"788558"}}